N/A N=51

NT-proBNP in ICU Postoperative/Posttraumatic Patients With Shock

SIRS · Sepsis · Shock · Critically Ill · Multiple Organ Dysfunction Syndrome

Bottom Line

View on ClinicalTrials.gov: NCT00736723 ↗

Enrolled (actual)

Serious AEs

11.4%

Results posted

Jan 2017

Primary outcome: Primary: Pattern of NT-proBNP, Biomarkers and Surface Markers on Leukocytes — 902; 4,429 pg/ml

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: —
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Ulm
Primary completion: Aug 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Pattern of NT-proBNP, Biomarkers and Surface Markers on Leukocytes	902; 4,429	—

Summary

The purpose of this study is to determine the course of NT-proBNP plasma concentrations in the context of confounding parameters in postoperative/posttraumatic critically ill patients with severe SIRS/sepsis and shock.

Eligibility Criteria

Inclusion Criteria

Critically ill, postoperative/posttraumatic patients with severe systemic inflammatory response syndrome (SIRS) or severe sepsis

Exclusion Criteria

Life expectancy < 24 hours
Participation in other trials
Known or suspected pregnancy
Contraindications for transesophageal echocardiography (TEE): severe disease of the esophagus (hernia, strictures, esophageal resection, severe bleeding disorders)

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00736723). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.